Close Menu

Tekmira Pharmaceuticals said last week that it has stopped a phase I study of its siRNA-based hypercholesterolemia drug ApoB SNALP.

While the drug was well tolerated and showed some signs of clinical activity, Tekmira said that it has put the phase I program on hold in order to select a new siRNA and drug-delivery formulation for development. The new agent is expected to be "several-fold more potent than the current formulation," the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.